# PD1-CD19-CART in Patients With r/r B-cell Lymphoma

> **NCT04213469** · NA · COMPLETED · sponsor: **Bioray Laboratories** · enrollment: 20 (actual)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells

## Key facts

- **NCT ID:** NCT04213469
- **Lead sponsor:** Bioray Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-13
- **Primary completion:** 2021-11-01
- **Final completion:** 2023-11-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04213469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04213469, "PD1-CD19-CART in Patients With r/r B-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04213469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*